专题:Mechanisms of Drug-Induced Hepatotoxicity

This cluster of papers focuses on the mechanisms, risk factors, biomarkers, and management of drug-induced hepatotoxicity, with a specific emphasis on acetaminophen-induced liver injury. It covers topics such as oxidative stress, mitochondrial dysfunction, HLA genotype associations, idiosyncratic reactions, and the role of liver transplantation in severe cases.
最新文献
<i>Tridax procumbens</i> Leaf Extract Mitigated Vincristine-Induced Organ Pathology and Oxidative Imbalances in Wistar Rats

article Full Text OpenAlex

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models

article Full Text OpenAlex

Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023

article Full Text OpenAlex

Silymarin as a Redox-Signalling and Proteostasis Modulator

article Full Text OpenAlex

Effect of Essential Phospholipids in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial

article Full Text OpenAlex

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury

article Full Text OpenAlex

Acute-on-chronic liver failure and immune dysregulation: Systemic inflammation and immunoparesis paradox

article Full Text OpenAlex

Cirsimaritin attenuates cisplatin-induced hepatotoxicity via modulation of oxidative stress and NF-κB/Akt signaling pathways in rats

article Full Text OpenAlex

Recommendations on Drug Selection and Dose Adjustment for Patients with Liver Cirrhosis: Results from a Multidisciplinary Expert Panel

article Full Text OpenAlex

Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD

article Full Text OpenAlex

近5年高被引文献
Global burden of liver disease: 2023 update

review Full Text OpenAlex 1967 FWCI394.5426

EASL Clinical Practice Guidelines on acute-on-chronic liver failure

article Full Text OpenAlex 310 FWCI57.2072

Nirmatrelvir Plus Ritonavir: First Approval

review Full Text OpenAlex 298 FWCI28.028

EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis

article Full Text OpenAlex 292 FWCI36.2888

Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity

review Full Text OpenAlex 265 FWCI18.1028

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

review Full Text OpenAlex 255 FWCI44.5085

Acute-on-Chronic Liver Failure Clinical Guidelines

review Full Text OpenAlex 234 FWCI27.015

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

article Full Text OpenAlex 234 FWCI33.072

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

article Full Text OpenAlex 209 FWCI42.0173

International Journal of Pharmacy and Pharmaceutical Science

paratext Full Text OpenAlex 206 FWCI0